alpha-MSH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
== History == Dihydroergotamine was synthesized by Albert Hofmann and Werner Stoll at Sandoz in 1943. It was first described in the scientific literature that same year. Dihydroergotamine was first approved for medical use under the brand name D.H.E. 45 in 1946. Dihydroergotamine is derived from ergot, a fungus that grows on rye and other grains.
=== Available forms === Suvorexant is available in the form of 5, 10, 15, and 20 mg oral film-coated tablets. It is provided as 10- and 30-tablet blister packs as well as 3-tablet starter packs. The availability of these different packs varies by country.
== Production == The dish gained popularity during the rationing in World War II, but declined over the following decades. The "nose-to-tail eating" trend has resulted in greater demand for faggots in the 21st century; British supermarket chain Waitrose once again sold beef faggots from 2014. In 2018, it was estimated that "tens of millions" of faggots were eaten every year.
Neuroscience is the scientific study of the nervous system (the brain, spinal cord, and peripheral nervous system), its functions, and its disorders. It is a multidisciplinary science that combines physiology, anatomy, molecular biology, developmental biology, cytology, psychology, physics, computer science, chemistry, medicine, statistics, and mathematical modeling to understand the fundamental and emergent properties of neurons, glia, and neural circuits. The understanding of the biological basis of learning, memory, behavior, perception, and consciousness has been described by Eric Kandel as the "epic challenge" of the biological sciences. The scope of neuroscience has broadened over time to include different approaches used to study the nervous system at different scales. The techniques used by neuroscientists have expanded enormously, from molecular and cellular studies of individual neurons to imaging of sensory, motor, and cognitive tasks in the brain.
Sources: en.wikipedia.org
Spironolactone has been found to decrease the bioavailability of high doses of oral estradiol. Although widely employed, the use of spironolactone as an antiandrogen in transgender women has recently been questioned due to the various shortcomings of the medication for such purposes. Cyproterone acetate is an antiandrogen and progestin which is used in the treatment of numerous androgen-dependent conditions and is also used as a progestogen in birth control pills. It works primarily as an antigonadotropin, secondarily to its potent progestogenic activity, and strongly suppresses gonadal androgen production. Cyproterone acetate at a dosage of 5 to 10 mg/day has been found to lower testosterone levels in men by about 50 to 70%, while a dosage of 100 mg/day has been found to lower testosterone levels in men by about 75%. The combination of 25 mg/day cyproterone acetate and a moderate dosage of estradiol has been found to suppress testosterone levels in transgender women by about 95%. In combination with estrogen, 10, 25, and 50 mg/day cyproterone acetate have all shown the same degree of testosterone suppression. In addition to its actions as an antigonadotropin, cyproterone acetate is an androgen receptor antagonist. However, this action is relatively insignificant at low dosages, and is more important at the high doses of cyproterone acetate that are used in the treatment of prostate cancer (100–300 mg/day). Cyproterone acetate can cause elevated liver enzymes and liver damage, including liver failure.
== Modern era == Further evidence of the threat that lead posed to humans was discovered in the late 19th and early 20th centuries. Mechanisms of harm were better understood, lead blindness was documented, and the element was phased out of public use in the United States and Europe. The United Kingdom introduced mandatory factory inspections in 1878 and appointed the first Medical Inspector of Factories in 1898; as a result, a 25-fold decrease in lead poisoning incidents from 1900 to 1944 was reported. Most European countries banned lead paint—commonly used because of its opacity and water resistance—for interiors by 1930. The last major human exposure to lead was the addition of tetraethyllead to gasoline as an antiknock agent, a practice that originated in the United States in 1921. It was phased out in the United States and the European Union by 2000. In the 1970s, the United States and Western European countries introduced legislation to reduce lead air pollution. The impact was significant: while a study conducted by the Centers for Disease Control and Prevention in the United States in 1976–1980 showed that 77.8% of the population had elevated blood lead levels, in 1991–1994, a study by the same institute showed the share of people with such high levels dropped to 2.2%. The main product made of lead by the end of the 20th century was the lead–acid battery. From 1960 to 1990, lead output in the Western Bloc grew by about 31%.
By August, eight of the nine republics, except Ukraine, had approved the draft of the new Treaty with some conditions. Ukraine did not agree on the terms of the Treaty. In the simultaneous Ukrainian republican referendum on 17 March, the majority of residents of Ukraine supported joining the Union on the basis of the 16 July 1990 Declaration of State Sovereignty of Ukraine. In addition, most of autonomous republics expressed the desire to raise their status and to be a party to the new Soviet treaty and declared sovereignty and self-promotion to republics during the parade of sovereignties in the months following the initial proposal from July 1990. Most of them participated in the Novo-Ogaryovo process to draft the treaty, and the status of former autonomous republics was a major point of contention among participants. On July 12, 1991, the Supreme Soviet passed the resolution "About the draft treaty on Union of Sovereign States" to state its stance on the matter that each of "the subjects of the federation, including both the sovereign states - the republics - and the republics incorporated within them on a treaty or constitutional basis" "possesses the right to sign the text of the Union Treaty". As a compromise, the final draft of the treaty allowed a state to join the Union as a part of another state, but only the nine republics were invited to sign it at Novo-Ogaryovo on July 23. Following the August coup, the New Union Treaty was further reformed into the Commonwealth of Independent States.
== In popular culture == In Jules Verne's 1870 novel, 20,000 Leagues Under The Sea, the story is written in the form of narration from journal entries by Professor Pierre Aronnax, a naturalist from the Paris Museum of Natural History (the name of the museum at the time). The Gallery of Palaeontology and Comparative Anatomy and other parts of Jardin des Plantes was a source of inspiration for French graphic novelist Jacques Tardi. The gallery appears on the first page and several subsequent pages of Adèle et la bête (Adèle and the Beast; 1976), the first album in the series of Les Aventures extraordinaires d'Adèle Blanc-Sec. The story opens with a 136-million-year-old pterodactyl egg hatching, and a live pterodactyl escaping through the gallery glass roof, wreaking havoc and killing people in Paris. The Gallery of Palaeontology and Comparative Anatomy returned the favour by placing a life size cardboard cutout of Adèle and the hatching pterodactyl in a glass cabinet outside the main entrance on the top floor balcony. The Pulitzer Prize–winning novel All the Light We Cannot See, by Anthony Doerr, partially takes place at the MNHN; the father of the protagonist Marie-Laure works as the chief locksmith of the museum. The story also makes many references to Jules Verne's novel 20,000 Leagues Under the Seas, and the fictional naturalist and narrator Professor Pierre Aronnax. Marie-Laure was gifted braille books of the novel by her father.
== Sources == Magurno, B. A.; Pearlstein, S., eds. (1981). Proceedings of the conference on nuclear data evaluation methods and procedures. BNL-NCS 51363 (PDF). Vol. II. Upton: Brookhaven National Laboratory. Archived (PDF) from the original on March 8, 2021. Retrieved August 6, 2014. Miner, William N.; Schonfeld, Fred W. (1968). "Plutonium". In Clifford A. Hampel (ed.). The Encyclopedia of the Chemical Elements. New York (NY): Reinhold Book Corporation. pp. 540–546. LCCN 68029938.
Sources: en.wikipedia.org
== Personal life == Yates lives in Marbella with his wife, Brazilian fitness model Glauce "Gal" Ferreira, whom he had met at the 2008 Arnold Classic. His son with his ex-wife Deb is also a bodybuilder and the two work closely together. Yates practises yoga every day and has described yoga and meditation as life-altering experiences. He has endorsed the use of psychedelics such as ayahuasca for religious and spiritual purposes. He is open about his cannabis use, which predates his bodybuilding career; in a July 2017 appearance on The Joe Rogan Experience, he stated that cannabis has "anti-cancer" properties and said that he is an advocate for its legalisation for this reason in addition to its relaxing properties and temporary increases in respiratory capacity. Yates revealed his belief in Holocaust denial theories whilst being interviewed by Dave Palumbo in April 2018, claiming that the Holocaust death toll had been "exaggerated" and that two forensic studies (which he did not provide the names of) had concluded that no gas was ever used at the Auschwitz concentration camp.
Compared to the Basic Test it is more sensitive to operator technique, and as a result may be less precise. Acute Toxicity Solid-Phase Test is a procedure that allows the test organism to come in direct contact with the solid sample as particulate in an aqueous suspension. Normally, this test provides results indicating equal or higher toxicity when compared to eluate or pore water tests of the same sample. This is due to either equal or increased bioavailability resulting from direct contact. This test is subject to several sources of interference of luminescence including loss of bacteria from effects other than toxicity such as filtration of the sample; absorption of light due to color; and scattering of light due to turbidity. Corrections can be made by testing a sample of similar particle composition that is known to not be toxic. This test consists of two controls and 13 sample dilutions in duplicate. The Solid-Phase Test exposes the bacteria in such a way that is not always possible with pore water and elutriate. Acute Toxicity Comparison & Inhibition Tests are the best procedures for testing samples with a low level of toxicity when an ECxx can not be determined using the Basic Test. These protocols are recommended for testing waste water treatment plant effluent, stormwater runoff, drinking water, pore water, and eluate. These tests use multiple replicates of a sample at a single concentration. Similar to the Basic Test, the Comparison Test protocol uses zero time light readings used for correcting the timed light level readings.
== Career == After gaining her doctorate, Ala-Kokko moved to Thomas Jefferson University in Philadelphia, United States, to carry out postdoctoral research in the group of Darwin Prockop. While there, Ala-Kokko focused her attention more directly on describing the structure, function and possible errors in genes that code for collagen proteins. She worked at Thomas Jefferson University as a research associate from 1987 to 1989, and as an instructor from 1989 to 1991. In 1990, Ala-Kokko was granted title of docent by the University of Oulu in the field of medical biochemistry. Her research work continued to be based in Philadelphia until 1997, when she was selected as a senior research fellow by the Academy of Finland. In the same year, Ala-Kokko also started at MCP Hahnemann University as an adjunct associate professor. In 2000, Ala-Kokko started work at the gene therapy centre of Tulane University in New Orleans. She worked there as an associate professor, and later became a full professor with tenure. In 2003 she was named professor of medical biochemistry and molecular biology at the University of Oulu. She left Tulane University in 2004. The company Connective Tissue Gene Tests was founded by Ala-Kokko in 2004 with her husband James Hyland. They offer over a thousand tests which function as molecular diagnostic tests of connective tissue disorders. As of 2018 her responsibility in the company is for research, development and technology. She is also responsible for overseeing all the tests that the company produces.
Euromac, an EU-funded consortium of medical and research institutes across Europe which is building a patient registry and raising standards of care for people with McArdle Disease. Archived 2021-04-22 at the Wayback Machine International Association for Muscle Glycogen Storage Disease (IamGSD). Walking With McArdle's - IamGSD videos EUROMAC Introduction - Video about McArdle disease and the EUROMAC Registry of McArdle disease and other rare glycogenoses patients
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.